Moderna Isn’t Enforcing COVID-19 Vaccine IP

However, it should be noted that its patents have come under scrutiny more than once during the pandemic. Earlier in the year, Moderna failed to invalidate an Arbutus Biopharma patent that may affect their launch. Public Citizen claims the U.S. government has partial claim to Moderna’s COVID-19 patents and notes that U.S. taxpayers will end up paying for the vaccine twice: once for initial research, and again for procurement of doses.